In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Abeona Therapeutics Inc (NASDAQ: ABEO) closed the day trading at $4.78 down -0.62% from the previous closing price of $4.81. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 1.29 million shares were traded. ABEO stock price reached its highest trading level at $4.855 during the session, while it also had its lowest trading level at $4.655.
Ratios:
For a better understanding of ABEO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.65 and its Current Ratio is at 6.73. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 16 ’25 when Seshadri Vishwas sold 249 shares for $5.49 per share. The transaction valued at 1,366 led to the insider holds 1,189,818 shares of the business.
Seshadri Vishwas bought 249 shares of ABEO for $1,366 on Oct 16 ’25. On Sep 29 ’25, another insider, O’Malley Brendan M., who serves as the SVP, Chief Legal Officer of the company, sold 9,366 shares for $5.39 each. As a result, the insider received 50,516 and left with 350,763 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 245111424 and an Enterprise Value of 43669416. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 612.78 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 109.174 whereas that against EBITDA is -0.603.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.45, which has changed by -0.22544283 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -17.47%, while the 200-Day Moving Average is calculated to be -17.33%.
Shares Statistics:
Over the past 3-months, ABEO traded about 1.02M shares per day on average, while over the past 10 days, ABEO traded about 1782780 shares per day. A total of 51.25M shares are outstanding, with a floating share count of 45.68M. Insiders hold about 10.91% of the company’s shares, while institutions hold 66.14% stake in the company. Shares short for ABEO as of 1760486400 were 9188242 with a Short Ratio of 9.04, compared to 1757894400 on 8733509. Therefore, it implies a Short% of Shares Outstanding of 9188242 and a Short% of Float of 19.18.
Earnings Estimates
The performance of Abeona Therapeutics Inc (ABEO) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.05 and low estimates of -$0.27.
Analysts are recommending an EPS of between $1.15 and -$1.45 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.08, with 4.0 analysts recommending between $0.15 and -$0.47.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $21.65M. There is a high estimate of $27.18M for the next quarter, whereas the lowest estimate is $12M.
Based on 7 analysts’ estimates, the company’s revenue will be $116.68M in the next fiscal year. The high estimate is $140.3M and the low estimate is $96.1M.
